🔗 Share this article

Ex-government leader Sunak has strengthened his call for a focused testing initiative for prostate cancer.

In a recently conducted interview, he declared being "convinced of the critical importance" of introducing such a system that would be economical, achievable and "preserve countless lives".

His statements emerge as the UK National Screening Committee reconsiders its ruling from half a decade past against recommending standard examination.

Journalistic accounts suggest the authority may maintain its existing position.

Olympic Champion Contributes Support to Campaign

Champion athlete Sir Hoy, who has advanced prostate gland cancer, wants younger men to be tested.

He suggests reducing the eligibility age for accessing a prostate-specific antigen laboratory test.

At present, it is not routinely offered to healthy individuals who are below fifty.

The PSA test is disputed though. Levels can rise for factors apart from cancer, such as inflammation, causing false positives.

Critics maintain this can lead to unwarranted procedures and complications.

Targeted Screening Initiative

The proposed testing initiative would target men aged 45–69 with a hereditary background of prostate cancer and men of African descent, who experience increased susceptibility.

This population comprises around over a million men in the UK.

Research projections suggest the programme would cost £25m per year - or about £18 per patient - comparable to colorectal and mammary cancer testing.

The estimate involves 20% of suitable candidates would be contacted annually, with a seventy-two percent response rate.

Clinical procedures (scans and tissue samples) would need to rise by almost a quarter, with only a moderate increase in NHS staffing, as per the study.

Clinical Community Reaction

Various healthcare professionals remain sceptical about the effectiveness of screening.

They contend there is still a risk that individuals will be intervened for the disease when it is not strictly necessary and will then have to live with complications such as bladder issues and erectile dysfunction.

One prominent urological specialist stated that "The problem is we can often detect abnormalities that doesn't need to be addressed and we risk inflicting harm...and my apprehension at the moment is that risk to reward ratio needs adjustment."

Patient Experiences

Personal stories are also influencing the debate.

One case features a 66-year-old who, after requesting a prostate screening, was identified with the condition at the age of 59 and was advised it had progressed to his pelvic area.

He has since received chemical therapy, beam therapy and endocrine treatment but remains incurable.

The man advocates screening for those who are genetically predisposed.

"This is crucial to me because of my sons – they are 38 and 40 – I want them checked as quickly. If I had been examined at 50 I am certain I might not be in the circumstances I am now," he said.

Future Actions

The Screening Advisory Body will have to evaluate the evidence and viewpoints.

Although the latest analysis suggests the ramifications for personnel and capacity of a examination system would be achievable, some critics have contended that it would divert scanning capacity otherwise allocated to patients being cared for for different health issues.

The ongoing debate highlights the complicated trade-off between early detection and likely excessive intervention in prostate cancer care.